| scholarly article | Q13442814 |
| P50 | author | K. Rajender Reddy | Q69932454 |
| P2093 | author name string | Chojkier M | |
| McHutchison JG | |||
| Muir AJ | |||
| Pang PS | |||
| Subramanian GM | |||
| Symonds WT | |||
| Ryan M | |||
| Kowdley KV | |||
| Hyland RH | |||
| Di Bisceglie AM | |||
| Ghalib R | |||
| Pockros PJ | |||
| Schiff E | |||
| Shiffman ML | |||
| Fried MW | |||
| Gordon SC | |||
| Bernstein DE | |||
| An D | |||
| Herring R | |||
| Lawitz E | |||
| Pound D | |||
| Rossaro L | |||
| Rustgi V | |||
| Svarovskaia E | |||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ledipasvir | Q15409409 |
| sofosbuvir | Q2502747 | ||
| P304 | page(s) | 1879-88 | |
| P577 | publication date | 2014-05-15 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis | |
| P478 | volume | 370 |
| Q39077941 | "Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic? |
| Q58788714 | 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C |
| Q37629097 | A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection |
| Q41845647 | A Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Hepatitis C Virus Genotype 1 |
| Q40888934 | A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. |
| Q36743639 | A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection |
| Q93048181 | A Randomized Controlled Trial to Assess the Impact of Clinical Pharmacy Interventions on Treatment Outcomes, Health Related Quality of Life and Medication Adherence Among Hepatitis C Patients |
| Q85608080 | A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on |
| Q95463423 | A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Dac |
| Q94387922 | A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • Boston, MassachusettsSpecial Reporting on:• Evaluati |
| Q48553648 | A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects |
| Q35449696 | A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. |
| Q41104253 | A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus |
| Q39751806 | A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. |
| Q87096148 | A pill a day keeps HCV away |
| Q37279260 | A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies |
| Q42400012 | APASL consensus statements and recommendation on treatment of hepatitis C. |
| Q30250088 | APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. |
| Q38314738 | Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease? |
| Q57070331 | Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir |
| Q38272635 | Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis |
| Q37116816 | Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens |
| Q38556401 | Advances in hepatitis C therapies |
| Q26770036 | Advances in hepatitis C therapy: What is the current state - what come's next? |
| Q47291511 | Advances in the treatment of HIV/HCV coinfection in adults |
| Q47548361 | All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings |
| Q36138623 | All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality |
| Q91948494 | Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir |
| Q39883996 | An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens |
| Q38515827 | An overview of new biomolecular pathways in pathogen-related cancers |
| Q35100139 | An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver |
| Q28070279 | Anti-hepatitis C virus drugs and kidney |
| Q37130025 | Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection |
| Q40745083 | Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190. |
| Q36870118 | Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective |
| Q39973981 | Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. |
| Q38341993 | Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. |
| Q91897220 | Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study |
| Q92581566 | Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C |
| Q38980602 | Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care |
| Q64285976 | Association Between Baseline Creatinine Clearance and Treatment Failure in Patients With Hepatitis C Virus Treated With Ledipasvir and Sofosbuvir |
| Q39911124 | Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus |
| Q40719246 | Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus |
| Q33629538 | Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. |
| Q41930106 | Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. |
| Q50884395 | Baseline HCV-RNA levels in genotype 1 chronic hepatitis C patients: The role of different cut-off points. |
| Q37612271 | Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. |
| Q57296265 | Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life |
| Q36030505 | Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Coinfected Recipients in the United States |
| Q37056536 | Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial |
| Q35901512 | Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates |
| Q42370370 | C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients |
| Q34775524 | CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults |
| Q37100669 | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment |
| Q42978825 | CROI 2015: Highlights of Viral Hepatitis Therapy |
| Q38652183 | Cancer Prevention: Lessons Learned and Future Directions |
| Q36164438 | Cancers in Australia in 2010 attributable to infectious agents |
| Q40328430 | Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma. |
| Q91599703 | Changing Treatment Landscape of Hepatitis C Virus Infection Among Penitentiary Inmates |
| Q27011203 | Changing the face of hepatitis C management - the design and development of sofosbuvir |
| Q53690933 | Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort. |
| Q40548267 | Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens |
| Q40646372 | Chronic Hepatitis C - Therapeutic Options in 2016 |
| Q26781770 | Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies |
| Q36981033 | Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies |
| Q50125687 | Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals |
| Q26773585 | Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective |
| Q36015474 | Chronic Kidney Disease and Related Long-Term Complications After Liver Transplantation |
| Q38538107 | Chronic hepatitis B: A wave of new therapies on the horizon |
| Q40057348 | Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. |
| Q26775011 | Chronic hepatitis C: This and the new era of treatment |
| Q28080225 | Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C |
| Q38837583 | Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C. |
| Q40677674 | Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein |
| Q33440436 | Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. |
| Q40278965 | Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy |
| Q26746910 | Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective |
| Q56890425 | Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial |
| Q90353204 | Comorbid hepatitis C does not modulate prevalence or severity of diabetic retinopathy |
| Q39690146 | Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. |
| Q31143582 | Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration |
| Q46661989 | Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity |
| Q36190873 | Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance |
| Q28075544 | Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection |
| Q92625996 | Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions |
| Q35759025 | Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients |
| Q33629561 | Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1 |
| Q36238515 | Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany |
| Q54984374 | Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations. |
| Q40302226 | Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. |
| Q35619161 | Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States |
| Q40720905 | Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. |
| Q33652027 | Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. |
| Q36479439 | Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. |
| Q35088460 | Cost-effectiveness of screening for hepatitis C in Canada |
| Q40546478 | Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan |
| Q38295834 | Cure of HCV related liver disease |
| Q42997856 | Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual |
| Q39151677 | Current therapy for chronic hepatitis C: The role of direct-acting antivirals |
| Q38545043 | Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis |
| Q40960952 | Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison |
| Q38628237 | Daclatasvir for the treatment of chronic hepatitis C. |
| Q38216586 | Daclatasvir for the treatment of hepatitis C virus infection. |
| Q38665683 | Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens? |
| Q28067411 | Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need |
| Q38515906 | Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace |
| Q47555750 | Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study |
| Q47551020 | Diagnosis and Management of Hepatitis C Infection in Primary Care Settings |
| Q38628831 | Diagnosis and management of hepatitis C. |
| Q40057172 | Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. |
| Q44337654 | Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy |
| Q40333567 | Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis |
| Q35598309 | Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent |
| Q88868398 | Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community |
| Q40107697 | Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study |
| Q38826176 | Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights |
| Q59349760 | Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review |
| Q41201956 | Direct-acting antiviral treatment of chronic hepatitis C infection |
| Q40333753 | Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients |
| Q57389418 | Direct-acting antivirals for chronic hepatitis C |
| Q34557595 | Direct-acting antivirals for chronic hepatitis C. |
| Q34045760 | Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives |
| Q40118647 | Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT). |
| Q40809705 | Disconnected by design: analytic approach in treatment networks having no common comparator |
| Q89718158 | Discontinuation of new hepatitis C drugs among Medicare patients |
| Q59361006 | Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population |
| Q39010715 | Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes? |
| Q36376114 | Doubling of coastal flooding frequency within decades due to sea-level rise |
| Q28547529 | Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade |
| Q28550311 | Drug Pricing Evolution in Hepatitis C |
| Q40143109 | Drug interactions in HIV-infected patients treated for hepatitis C. |
| Q37735902 | Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis |
| Q59349441 | Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir |
| Q40506459 | Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir. |
| Q38554604 | Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects. |
| Q38714156 | Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection |
| Q35928072 | Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data |
| Q36327141 | Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV) |
| Q37027342 | Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients |
| Q38688748 | Economic study of the value of expanding HCV treatment capacity in Germany |
| Q38909432 | Effect of Chronic Hepatitis C Virus Treatment by Combination Therapy on Cardiovascular System |
| Q27468855 | Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets |
| Q40129813 | Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. |
| Q39449507 | Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response |
| Q30841159 | Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System |
| Q38748387 | Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. |
| Q52642614 | Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study. |
| Q40565832 | Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials |
| Q28074783 | Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis |
| Q40297644 | Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. |
| Q38375284 | Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study |
| Q34451681 | Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a |
| Q40328514 | Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study |
| Q38402939 | Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease. |
| Q53837635 | Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. |
| Q90156215 | Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients |
| Q39262589 | Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials |
| Q38837174 | Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. |
| Q26771458 | Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis |
| Q57827106 | Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients |
| Q38861177 | Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. |
| Q54256408 | Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection. |
| Q39058953 | Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection |
| Q39025640 | Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System |
| Q59351829 | Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL |
| Q40098679 | Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety |
| Q33825807 | Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission |
| Q41564943 | Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting |
| Q47555660 | Engineered Livers for Infectious Diseases |
| Q28085718 | Enhancing our understanding of current therapies for hepatitis C virus (HCV) |
| Q56395674 | Epidemic history of hepatitis C virus genotypes and subtypes in Portugal |
| Q57297223 | Epidemiology and Elimination of HCV-Related Liver Disease |
| Q26777506 | Era of direct acting antivirals in chronic hepatitis C: Who will benefit? |
| Q34246440 | Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy |
| Q36336005 | Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China |
| Q59357943 | Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection |
| Q59356417 | Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis |
| Q39481949 | Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study |
| Q36738517 | Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? |
| Q57490314 | Expert opinion on the management of hepatitis C infection in Kuwait |
| Q26822400 | Finally sofosbuvir: an oral anti-HCV drug with wide performance capability |
| Q38353529 | Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. |
| Q30368260 | Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report. |
| Q38888859 | Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. |
| Q89912010 | Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy |
| Q30235178 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C |
| Q38820559 | Genotype 1 hepatitis C virus and the pharmacist's role in treatment. |
| Q40957442 | Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study |
| Q31012317 | HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape |
| Q26801602 | HCV Kinetic Models and Their Implications in Drug Development |
| Q41407052 | HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. |
| Q38707521 | HCV Prevalence in Asian Americans in California |
| Q97885926 | HCV Replicon Systems: Workhorses of Drug Discovery and Resistance |
| Q90058234 | HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic |
| Q37098242 | HCV cure for everyone or which challenges remain? |
| Q37368417 | HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. |
| Q38372939 | HCV management in resource-constrained countries. |
| Q38685577 | HCV-HIV co-infected patients: no longer a 'special' population? |
| Q41172135 | HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials |
| Q38733664 | HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. |
| Q93031499 | HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens |
| Q87113556 | Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury |
| Q40422150 | Healthcare resources are inadequate to address the burden of illness among HIV-infected male prisoners in Malaysia |
| Q89777684 | Hemophilia gene therapy comes of age |
| Q45875635 | Hemophilia gene therapy comes of age. |
| Q36650834 | Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus |
| Q28084654 | Hepatitis C |
| Q90834044 | Hepatitis C |
| Q56898303 | Hepatitis C (chronic) |
| Q26781743 | Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy |
| Q59352655 | Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection |
| Q38501726 | Hepatitis C Infection in the Elderly |
| Q40529775 | Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response |
| Q41555626 | Hepatitis C Screening: The Downstream Dissemination of Evolving Guidelines in a Resident Continuity Clinic |
| Q59350307 | Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016 |
| Q45325225 | Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population |
| Q42202758 | Hepatitis C beware--the end is nigh |
| Q26799924 | Hepatitis C cirrhosis: New perspectives for diagnosis and treatment |
| Q34439125 | Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review |
| Q34044333 | Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus |
| Q38382431 | Hepatitis C in Australian prisons: a national needs assessment |
| Q54208089 | Hepatitis C in Canada and the importance of risk-based screening. |
| Q33585021 | Hepatitis C in a New Era: A Review of Current Therapies |
| Q26773201 | Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon |
| Q35822155 | Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study |
| Q40989823 | Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. |
| Q39104215 | Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens |
| Q35783876 | Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens |
| Q30378509 | Hepatitis C treatment: where are we now? |
| Q28552909 | Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance |
| Q57295205 | Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development |
| Q57030951 | Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir |
| Q36158361 | Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir |
| Q92353675 | Hepatitis C virus infection and new treatment strategies |
| Q55381219 | Hepatitis C virus infection in children in the era of direct-acting antiviral. |
| Q38374284 | Hepatitis C virus therapeutic development: in pursuit of "perfectovir". |
| Q38602682 | Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. |
| Q90352549 | Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population |
| Q35501190 | Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade |
| Q27468916 | Hepatitis C virus: Promising discoveries and new treatments |
| Q38812892 | Hepatitis C-A clinical review |
| Q38635796 | Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. |
| Q42212155 | Hepatitis C: Treatment triumphs |
| Q57756376 | Hepatocellular carcinoma |
| Q57491226 | Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review |
| Q36651317 | High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study |
| Q40750705 | High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens |
| Q36997093 | Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan |
| Q38554500 | Host genetic variants influencing the clinical course of hepatitis C virus infection |
| Q55280981 | Host-targeting therapies for hepatitis C virus infection: current developments and future applications. |
| Q38257819 | Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle |
| Q36088575 | Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. |
| Q40338014 | Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir |
| Q38893104 | Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time |
| Q45323933 | Impact of Hepatitis C Virus Polymorphisms on Direct-Acting Antiviral Treatment Efficacy: Regulatory Analyses and Perspectives |
| Q35968616 | Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. |
| Q35501259 | Impact of all oral anti-hepatitis C virus therapy: A meta-analysis |
| Q40414089 | Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries |
| Q36354119 | Impact of hepatitis C status on 20-year mortality of patients with substance use disorders |
| Q35985401 | Impact of hepatitis C virus eradication on hepatocellular carcinogenesis |
| Q47605707 | Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia |
| Q26782017 | Impact of new treatment options for hepatitis C virus infection in liver transplantation |
| Q42190310 | Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis |
| Q36765588 | Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study |
| Q52819324 | Implementation of the Lancet Standing Commission on Liver Disease in the UK. |
| Q40171277 | Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. |
| Q40480520 | Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. |
| Q40501654 | In Vitro Study on Anti-Hepatitis C Virus Activity of Spatholobus suberectus Dunn. |
| Q59360894 | Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic |
| Q41039250 | Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011. |
| Q39692527 | Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada |
| Q30355190 | Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. |
| Q26783056 | Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance |
| Q92772696 | Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis |
| Q26781991 | Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes |
| Q38364524 | Innate and adaptive genetic pathways in HCV infection |
| Q54250224 | Interaction Between Hepatocellular Carcinoma and Hepatitis C Eradication With Direct-acting Antiviral Therapy. |
| Q26781331 | Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance |
| Q36837502 | Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration |
| Q26746563 | Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection |
| Q28087400 | Interferon-free combination therapies for the treatment of hepatitis C: current insights |
| Q34424151 | Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? |
| Q38530211 | Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. |
| Q40298785 | Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain |
| Q37035896 | Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis |
| Q38556915 | Is the 25-year hepatitis C marathon coming to an end to declare victory? |
| Q40791531 | JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. |
| Q35558268 | Labour productivity losses caused by premature death associated with hepatitis C in Spain. |
| Q42212780 | Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects |
| Q40466129 | Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. |
| Q38236179 | Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. |
| Q93052595 | Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Monoinfection Associated with a High Risk of Acute Liver Failure |
| Q36967076 | Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. |
| Q57821930 | Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men |
| Q41343312 | Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial |
| Q35019918 | Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection |
| Q40375140 | Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. |
| Q40634052 | Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection |
| Q99558446 | Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study |
| Q26769621 | Ledipasvir with sofosbuvir |
| Q47572592 | Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection |
| Q38740104 | Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective. |
| Q38793356 | Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection |
| Q40357542 | Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders |
| Q40248569 | Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial |
| Q41102465 | Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection |
| Q34454200 | Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection |
| Q41347499 | Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection |
| Q59356778 | Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population |
| Q36052231 | Ledipasvir/Sofosbuvir. |
| Q47547989 | Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. |
| Q34470061 | Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. |
| Q40027212 | Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. |
| Q45325427 | Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials |
| Q52594744 | Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. |
| Q41366537 | Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States |
| Q53692110 | Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. |
| Q38992214 | Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis. |
| Q41935150 | Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis |
| Q36166222 | Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. |
| Q58799836 | Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C |
| Q26740320 | Management of HCV-Associated Liver Cirrhosis |
| Q26781741 | Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review |
| Q31108752 | Management of Neurologic Manifestations in Patients with Liver Disease. |
| Q63684293 | Management of acute HCV infection in the era of direct-acting antiviral therapy |
| Q38395275 | Management of post transplant hepatitis C in the direct antiviral agents era. |
| Q56000943 | Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling |
| Q42290798 | Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature |
| Q38517530 | Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection |
| Q26773183 | MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations |
| Q40136277 | Modeling HCV cure after an ultra-short duration of therapy with direct acting agents |
| Q26864673 | Modelling hepatitis C therapy--predicting effects of treatment |
| Q36889376 | Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection. |
| Q36497834 | Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. |
| Q26782009 | Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies |
| Q40358244 | Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. |
| Q39031350 | NS5A inhibitors for the treatment of hepatitis C infection |
| Q39134413 | NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. |
| Q33672648 | Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China |
| Q42175503 | Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy |
| Q38875280 | New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection |
| Q33560181 | New Therapies for Hepatitis C Virus Infection |
| Q91599092 | New Treatments for Hepatitis C |
| Q93140950 | New all-oral HCV therapies for genotype 1: A final good-bye to interferon |
| Q38664453 | New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir |
| Q26800050 | New era for management of chronic hepatitis C virus using direct antiviral agents: A review |
| Q39016874 | New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). |
| Q41622257 | New kids on the block--step by step to an ideal HCV therapy |
| Q38233834 | New therapies for hepatitis C: considerations in patients with renal impairment. |
| Q26795407 | New treatment strategies for hepatitis C infection |
| Q37169457 | New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England |
| Q38703743 | New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir |
| Q45324359 | Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India |
| Q54256586 | No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients. |
| Q38743836 | No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection. |
| Q36396043 | No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL |
| Q38611842 | Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir |
| Q38318678 | Novel interventions to prevent HIV and HCV among persons who inject drugs |
| Q38262922 | Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. |
| Q41359261 | Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial |
| Q40239703 | Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial |
| Q38355057 | Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection |
| Q41514826 | On computer-intensive simulation and estimation methods for rare-event analysis in epidemic models. |
| Q41028724 | Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection |
| Q36333842 | Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection |
| Q26830643 | Oncogenes and RNA splicing of human tumor viruses |
| Q46644977 | Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients |
| Q38295826 | Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection |
| Q38295831 | Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients |
| Q92052156 | Optimizing Implementation of Hepatitis C Birth-Cohort Screening and Treatment Strategies: Model-Based Projections |
| Q38983274 | Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment |
| Q38249065 | Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection |
| Q30376341 | Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. |
| Q92981412 | Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs |
| Q39141420 | Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting |
| Q38470584 | Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals |
| Q48329834 | Overcoming the resistance to resistance testing: Collecting the data |
| Q36663835 | Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir |
| Q30393824 | Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. |
| Q40374154 | Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016? |
| Q57152417 | Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid Patients |
| Q35412591 | Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. |
| Q55017914 | Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection. |
| Q43047022 | Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C. |
| Q38927205 | Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions |
| Q41925685 | Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-naïve Hepatitis C virus Genotype 1-infected Patients without Cirrhosis Treated with a Simeprevir/Sofosbuvir/Ledipasvir Regimen |
| Q38500364 | Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C. |
| Q38995024 | Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. |
| Q55163317 | Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations. |
| Q35790397 | Predictive factors associated with hepatitis C antiviral therapy response |
| Q36358880 | Presence of Rheumatoid Factor during Chronic HCV Infection Is Associated with Expansion of Mature Activated Memory B-Cells that Are Hypo-Responsive to B-Cell Receptor Stimulation and Persist during the Early Stage of IFN Free Therapy. |
| Q35735285 | Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia |
| Q58564271 | Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank |
| Q39020651 | Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden |
| Q38826624 | Prevention and management of treatment failure to new oral hepatitis C drugs. |
| Q36751083 | Pricey pills for an even pricier problem |
| Q42850943 | Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012. |
| Q40300359 | Profile of Roche's cobas® HCV tests |
| Q40533002 | Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing |
| Q40775611 | Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake |
| Q38264060 | Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy |
| Q26798477 | Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications |
| Q26784261 | Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments |
| Q42213830 | QUEST for a cure for hepatitis C virus: the end is in sight |
| Q37726632 | Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir |
| Q40774593 | Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. |
| Q28545971 | Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection |
| Q36100521 | Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study |
| Q40320642 | Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. |
| Q40228687 | Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV |
| Q39398874 | Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients |
| Q93337430 | Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey |
| Q41923679 | Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt |
| Q47412911 | Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital |
| Q39326974 | Real-world challenges for hepatitis C virus medications: a critical overview |
| Q90079314 | Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study |
| Q64077800 | Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany |
| Q59360131 | Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system |
| Q39821108 | Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients |
| Q40211449 | Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis |
| Q37646759 | Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease |
| Q47203653 | Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients |
| Q26750476 | Recent Advances in Antiviral Therapy for Chronic Hepatitis C |
| Q36575497 | Recent advances in management of the HIV/HCV coinfected patient |
| Q28076883 | Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline |
| Q45325791 | Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. |
| Q90322598 | Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients |
| Q36051986 | Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C. |
| Q39301797 | Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. |
| Q50098527 | Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors. |
| Q59355074 | Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure |
| Q39610676 | Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial. |
| Q53624781 | Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics. |
| Q40631323 | Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. |
| Q47121490 | Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. |
| Q91757404 | Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives |
| Q38703524 | Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy |
| Q38355069 | Revolution in hepatitis C antiviral therapy |
| Q35746343 | Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production |
| Q37563692 | Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection |
| Q39574126 | Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. |
| Q26775002 | Ribavirin: Past, present and future |
| Q37130040 | Roadblocks to Accessing Direct-Acting Antiviral Agents for Treatment of Hepatitis C Virus Infection |
| Q26740216 | Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection |
| Q37216507 | SASLT guidelines: Update in treatment of Hepatitis C virus infection |
| Q38516135 | Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. |
| Q47202796 | Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients with Genotype 1 Hepatitis C Virus Infection and Cirrhosis |
| Q26745769 | Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C |
| Q31019494 | Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data |
| Q40171094 | Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older |
| Q45325211 | Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients |
| Q38742966 | Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C. |
| Q64083501 | Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort |
| Q40950331 | Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials |
| Q38818416 | Safety of direct antiviral agents in the management of hepatitis C. |
| Q38903835 | Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. |
| Q47614576 | Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey |
| Q47560335 | Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. |
| Q39259481 | Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial |
| Q38627508 | Shortening the duration of therapy for chronic hepatitis C infection |
| Q42174930 | Shorter treatments for hepatitis C: another step forward? |
| Q35491398 | Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? |
| Q40821688 | Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study |
| Q39479413 | Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). |
| Q37058681 | Sofosbuvir and ledipasvir for HIV/HCV co-infected patients |
| Q39690321 | Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus |
| Q40483611 | Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study |
| Q47404164 | Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. |
| Q57841241 | Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study |
| Q42207118 | Sofosbuvir for the treatment of hepatitis C virus infection |
| Q38383410 | Sofosbuvir for treatment of chronic hepatitis C. |
| Q36261373 | Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium |
| Q38643594 | Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection |
| Q39471334 | Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients |
| Q38954096 | Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence |
| Q26770024 | Sofosbuvir treatment and hepatitis C virus infection |
| Q55243551 | Sofosbuvir, a New Nucleotide Analogue, for the Treatment of Chronic Hepatitis C Infection. |
| Q26781773 | Sofosbuvir, a Significant Paradigm Change in HCV Treatment |
| Q38245128 | Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus |
| Q60047941 | Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? |
| Q49953662 | Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies |
| Q51754955 | Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. |
| Q89919346 | Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand |
| Q36460249 | Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea |
| Q39824771 | Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection |
| Q24562950 | Sofosbuvir: a novel oral agent for chronic hepatitis C |
| Q38222679 | Sofosbuvir: a review of its use in patients with chronic hepatitis C. |
| Q40642497 | Stability-Indicating Method and LC-MS-MS Characterization of Forced Degradation Products of Sofosbuvir |
| Q57813384 | Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges |
| Q35072099 | Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C |
| Q40565281 | Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report. |
| Q36446122 | Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. |
| Q50045992 | Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature |
| Q36073283 | Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report |
| Q40747468 | Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient |
| Q47680503 | Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome. |
| Q38957601 | Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity |
| Q36792338 | Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin |
| Q42164795 | Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q36270505 | Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein |
| Q90399068 | Thalassemia and hepatocellular carcinoma: links and risks |
| Q37555313 | The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations |
| Q64132787 | The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA |
| Q26777716 | The New Era of Interferon-Free Treatment of Chronic Hepatitis C |
| Q39254698 | The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection |
| Q26795559 | The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment |
| Q39449112 | The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit |
| Q41919051 | The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings |
| Q39137372 | The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. |
| Q64913900 | The dawn of a new era in the treatment of HCV infection: A view from the USA. |
| Q40326326 | The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. |
| Q41075768 | The dollars and sense of chronic hepatitis C infection management |
| Q40567336 | The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection |
| Q40215846 | The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens |
| Q41469280 | The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing |
| Q41682696 | The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study |
| Q55288229 | The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. |
| Q36286654 | The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study |
| Q28086947 | The new era of hepatitis C virus therapy |
| Q38634755 | The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics? |
| Q40078310 | The potential of signal peptide peptidase as a therapeutic target for hepatitis C. |
| Q47560943 | The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort |
| Q40201286 | The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience. |
| Q35750560 | The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments |
| Q88337935 | The role of external beam radiotherapy in the treatment of hepatocellular cancer |
| Q47552072 | The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection |
| Q38634221 | The safety of daclatasvir for the treatment of hepatitis C. |
| Q38996459 | The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? |
| Q38723427 | Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. |
| Q43034466 | Therapy of hepatitis C--back to the future. |
| Q38405059 | Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. |
| Q34524584 | Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline |
| Q38693657 | Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States |
| Q39112237 | Treatment Options in Hepatitis C. |
| Q28552691 | Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C |
| Q59354362 | Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients |
| Q37441421 | Treatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient Population |
| Q36076049 | Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis |
| Q38850965 | Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin |
| Q90106344 | Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region |
| Q55218109 | Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. |
| Q54268463 | Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. |
| Q40893681 | Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens |
| Q41087896 | Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin |
| Q26740219 | Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance |
| Q41437131 | Treatment of hepatitis C |
| Q52808389 | Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. |
| Q38431523 | Treatment of hepatitis C in difficult-to-treat patients |
| Q59351529 | Treatment of hepatitis C in special populations |
| Q36519126 | Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. |
| Q31160142 | Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. |
| Q41934079 | Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. |
| Q40292229 | Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. |
| Q41923073 | Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population |
| Q41624184 | Treatment of hepatitis C: what is known? |
| Q30235034 | Treatment optimization for HIV/HCV co-infected patients |
| Q40840459 | Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients |
| Q42173527 | Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials |
| Q40352380 | Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience |
| Q36030846 | Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011 |
| Q40604753 | Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients |
| Q64138093 | Undiagnosed HIV and HCV Infection in a New York City Emergency Department, 2015 |
| Q57157863 | Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now |
| Q38880996 | Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients |
| Q26775809 | Update on hepatitis C: Direct-acting antivirals |
| Q39049155 | Urgency to treat patients with chronic hepatitis C in Asia |
| Q38975165 | Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients |
| Q59355746 | Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations |
| Q91656685 | Velpatasvir and sofosbuvir: How will we use a new drug when the old agents work well? |
| Q64947352 | Velpatasvir y sofosbuvir: ¿Por qué utilizar un fármaco nuevo si los antiguos funcionan bien? |
| Q33760740 | Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection |
| Q92203399 | Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update |
| Q37721750 | Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies |
| Q92360165 | Viral hepatitis C treatment shortening - what is the limit? |
| Q51073649 | Viral hepatitis: towards the eradication of HCV and a cure for HBV. |
| Q38415842 | Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection |
| Q35592257 | Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study |
| Q38569681 | What does the pharmacological future of treating chronic hepatitis C look like? |
| Q38685566 | Why I do not treat patients for mild disease |
| Q28550101 | Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data |
Search more.